Protagonist Therapeutics (PTGX, Financial) has been reaffirmed with a "Buy" rating by the financial services firm HC Wainwright & Co., according to analyst Douglas Tsao. The analyst reiterated the price target for PTGX at $80.00 USD, maintaining the same target as before.
This report was released on May 19, 2025, reflecting HC Wainwright & Co.'s continued confidence in Protagonist Therapeutics. The current rating and the target price suggest that the firm anticipates potential growth and stability for PTGX in the near future.
The price target and rating have remained unchanged, indicating consistent expectations from the analyst regarding the stock's trajectory. Investors interested in PTGX are advised to consider this reiterated buy rating as part of their investment decision-making process.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Protagonist Therapeutics Inc (PTGX, Financial) is $69.00 with a high estimate of $82.00 and a low estimate of $41.00. The average target implies an upside of 55.09% from the current price of $44.49. More detailed estimate data can be found on the Protagonist Therapeutics Inc (PTGX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Protagonist Therapeutics Inc's (PTGX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
